Company Description
Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China).
Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms.
PCP, our key new drug candidate developed for the prevention of prostate cancer, is under phase II trials stage in Taiwan.
Another preclinical-stage key drug candidate, IC, is under preclinical studies for the treatment of interstitial cystitis.
| Country | Taiwan |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Fu-Feng Kuo |
Contact Details
Address: 23F-3, No. 95, Section 1, Xintai 5th Road Xizhi District, New Taipei City 221 Taiwan | |
| Phone | +886-2-2732-5205 |
| Website | healtheverbiotech.com |
Stock Details
| Ticker Symbol | MENS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001954488 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fu-Feng Kuo | Chairwoman of the Board of Directors and Chief Executive Officer |
| Fenglin Hsu | Director Nominee and Chief Technology Officer Nominee |
| Hung-Shu Fan | Independent Director Nominee |
| Pang-Chief Chi | Independent Director Nominee |
| Ming Tsan Hsu | Independent Director Nominee |
| Alfred Ying | Chief Financial Officer Nominee |
| Wanwen (Angela) Su | Chief Science Officer Nominee |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 31, 2025 | EFFECT | Notice of Effectiveness |
| Mar 27, 2025 | FWP | Free Writing Prospectus |
| Mar 27, 2025 | FWP | Free Writing Prospectus |
| Mar 11, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Feb 18, 2025 | FWP | Free Writing Prospectus |
| Feb 7, 2025 | FWP | Free Writing Prospectus |
| Feb 6, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 19, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Nov 21, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |